Volume 10, Issue 4, April – 2025 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1309

Case Study of Methylcobalamin in Pharmamarketing

Shivendra Mishra[1]; Devashish Jena[2]; Vikash Kumar Patel[3]; Sandip Kumar[4]

[1,2,3,4] S.N. College of Pharmacy Jaunpur.

Publication Date: 2025/05/02

Abstract: Pharmaceutical marketing is an activity which narrates the means and ways utilized by the drug companies in promoting their medication among medical practitioners, patients, and other customers. Pharmaceutical marketing encompasses a vast ground which comprises many activities such as direct-to-consumer marketing, doctor detailing, sampling of the drugs, electronic marketing, and market access models. Although the objective of pharmaceutical promotion is to grow the sale of medicines, it has the purpose of educating drug providers and patients in regard to therapy modalities too. Pharmaceutical marketing, however, is normally covered in moral dilemmas, particularly the effect that it places on drug costs and prescribing. The abstract below explores the fundamental aspects of pharmaceutical marketing, upcoming digital trends, regulatory concerns involved, and ethical considerations related to its practices. A balance and transparency that is effective is needed in order to ensure that marketing activities advance public health goals and offer trust to all concerned take holders.

Keywords; *Introduction, Important Element, Classification, Drug Profile, Market Survey.*

How to cite: Shivendra Mishra; Devashish Jena; Vikash Kumar Patel; Sandip Kumar (2025). Case Study of Methylcobalamin in Pharmamarketing. *International Journal of Innovative Science and Research Technology*, 10(4), 2140-2144 https://doi.org/10.38124/ijisrt/25apr1309

I. INTRODUCTION TO PHARMACEUTICAL MARKETING

Pharmaceutical promotion is a dynamic, inter-disciplinary, multidimensional, multidisciplinary field of study that only by coincidence happens to have the area of overlap with healthcare, business strategy, and regulatory science. It entails all promotional operations by pharmaceutical companies for raising awareness, availability, and sale of their medicinal goods, i.e., prescription medicines, OTC commodities, vaccines, and medical equipment. As global demand for healthcare options heightens, the pharmaceutical sector directs the way pharma is established and accepted by and in the market. Promotion of pharmaceuticals is thus an intrinsic process wherein creativity in research of drugs gets converted into viable therapeutic products available in the market.

The ultimate goal of marketing drugs is to make consumers and medical professionals aware of the existence and utility of specific products. Whereas overall consumer marketing can be challenging, pharmaceutical marketing has a few issues regarding the regulatory environment, ethical standards, and the reality that the end-consumer (the patient) rarely acts independently in deciding whether or not to purchase. Prescription medication decisions are instead negotiated between health care providers, payers, and regulatory agencies, all of whom have enormous power over what medications are used and how they're distributed.

Drug marketing started in the early decades of the 20th century but came into full existence only in the later decades of the century with the proliferation of mass media and the presence of multinational drug firms. Originally focused on physician-led promotions such as detailing (physician visits by sales representatives at doctors' offices), free samples, and pharmaceutical industry advertising in medical journals, the industry now encompasses a wide range of channels, including digital channels, social media, direct-to-consumer (DTC) television advertising, and multichannel marketing campaigns.

One of the most distinctive aspects of pharmaceutical promotion is the direct-to-consumer approach to advertising, which is applied most extensively in countries like the United States and New Zealand, where it is legally acceptable. With the help of online, print, and television advertisements, drug companies are able to promote directly to patients, inviting them to visit their physicians for a specific treatment. Although DTC advertising has raised public health awareness of disease and treatment, it has been condemned for the risk it poses to promote overmedication, distort risk-benefit orientations, and contribute to healthcare expenses.

Besides this, progress in digital health and data analysis has revolutionized pharma marketing. With the use of electronic health records, patient data management systems, and predictive analytics, organizations have been able to leverage more accurate and targeted marketing measures. Digital advertising campaigns, webinars, tele-detailing,

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1309

influencer marketing, and mobile health apps are a fee of next-generation initiatives adopted in today's pharma marketing.

Despite being vital, promotion of drugs is a matter of contentious regulatory and ethical issue. Matters of drug promotion transparency, conflict of interest, and drug company promotion on prescriber behavior are matters that are contentious in nature. Organizations such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national health regulatory agencies have the responsibility of ensuring that practices in marketing are kept in regard to truthfulness, fairness, and protection of patients' safety.

Apart from the regulatory problem, the pharma sector is also faced with issues of public trust, particularly in the aftermath of drug price scandals, opioid promotion, and hard-sell promotion scandals. Pharma firms thus increasingly resort to value-based marketing strategies where clinical evidence, patient outcomes, and long-term health dividends are prioritized over short-term commercial success.

In general, pharma marketing is a delicate but essential pursuit in the healthcare system. It must be an artful balance of pushing innovation forward, educating stakeholders, and following ethical and regulatory guidelines. As the company continues to develop with new technologies, shifting consumer values, and increasing global health demands, pharmaceutical marketers' initiatives and responsibilities will chart the course of medicine and patient care for the next two decades.

Pharma marketing is a specialty marketing profession promoting medicine and healthcare therapies to healthcare professionals, healthcare organizations, and even occasionally to patients. Here follows a formatted overview of pharmaceutical marketing

II. PHARMACEUTICAL MARKETING: IMPORTANT ELEMENTS

➢ *Target Groups*

- *Healthcare Professionals (Hcps)*

✓ Physicians
✓ Pharmacists
✓ Nurses
✓ Hospital Administrators
✓ Patients / Consumers:
✓ Direct-to-consumer (DTC) advertising (less prevalent in the U.S. and New Zealand)
✓ Payers / Insurers:
✓ Health insurance payers
✓ Pharmacy benefit managers (PBMs)
✓ Sales Representatives (Med Reps):
✓ In-person office calls to physicians (referred to as "detailing")
✓ Supply samples, info, and education materials
✓ Medical Conferences & CMEs:
✓ Event sponsorship and continuing medical education
✓ Journal Advertising & E-detailing:
✓ Medical journal advertisements
✓ Online presentations and doctor websites

- *Direct-To-Consumer (DTC) Marketing*

✓ TV, Radio, and Print Ads
✓ Digital Ads (Social Media, Google, Health Sites)
✓ Patient Awareness Campaigns

- *Pharmaceutical Marketing Strategies*

✓ Product Positioning
✓ KOL (Key Opinion Leader) Engagement
▪ Opinion-leading physicians or researchers who endorse and promote the drug

- Market Access & Pricing Strategy

✓ Insurance companies and hospital negotiation
✓ Utilization of value-based- Brand extension through:
✓ New indications
✓ Extended-release formulations
✓ Combination products
✓ Tools & Channels
✓ CRM Tools (e.g., Veeva, Salesforce Health Cloud)
✓ Market Research & Analytics
✓ Medical Science Liaisons (MSLs)
✓ Webinars & online CME platforms

- Regulations & Compliance

Marketing is closely regulated based on the products' nature. Important organizations include

✓ FDA (USA)
✓ EMA (Europe)
✓ PMDA (Japan)
✓ Local Drug Authorities(country-based)

III. METHYLCOBALAMIN

Methylcobalamin is one of the naturally occurring and biologically active forms of Vitamin B12, a water-soluble vitamin that is required for many physiological functions. It is an essential ingredient in neurological function, red blood cell production, and DNA synthesis.

In contrast to the synthetic derivatives like cyanocobalamin, methylcobalamin does not need to be converted in the body and hence is easily bioavailable and more potent, particularly for the management of neurological disorders and Vitamin B12 deficiency.

➢ *What Is Methylcobalamin?*

Methylcobalamin is a form of Vitamin B12 coenzyme that plays an essential role in the health of nerve cells, brain function and the formation of red blood cells and DNA. Among all the many forms of Vitamin B12, methylcobalamin

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1309

is an active and easy-to-use form for the body without it needing to be converted.

➢ *Chemical and Pharmacological Profile*

- IUPAC Name:Coα-[α-(5,6-dimethylbenzimidazolyl)]-Coβ-methylcobalamin
- Molecular Formula: $C_{63}H_{91}CoN_{13}O_{14}P$
- Molecular Weight: ~1344.38 g/mol
- Appearance:Red crystalline powder
- Solubility: Water-soluble

➢ *Mechanism of Action*

Methylcobalamin is a coenzyme in:

- Methionine synthase reaction (homocysteine to methionine conversion)
- This process is essential for methylation reactions such as DNA synthesis, neurotransmitter synthesis, and myelin sheath formation.

By promoting methylation and repair of the neurons, methylcobalamin is especially useful in neurological and neurodegenerative disorders.

Medical and Therapeutic Applications

➢ *Methylcobalamin Is Used To*

- Treat Vitamin B12 deficiency
- Facilitate nerve regeneration
- Control peripheral neuropathy (particularly in diabetes)
- Enhance symptoms in megaloblastic anemia
- Facilitate therapy in ALS, chronic fatigue syndrome, and certain autism spectrum disorders

➢ *Dosage Forms and Routes of Administration*

- Oral capsules/tablets
- Sublingual tablets (for faster absorption)
- Injections (intramuscular or intravenous)
- Frequently found in combination products with vitamins B1 (thiamine) and B6 (pyridoxine)

➢ *Pharmacokinetics*

- Absorption: Most absorbed in ileum; sublingual and injectable forms avoid gastrointestinal absorption
- Distribution: Binds to transcobalamin II for tissue transport
- Metabolism: Not extensively metabolized before use
- Excretion: Primarily excreted via urine

➢ *Benefits of Methylcobalamin (Over Other B12 Forms)*

- Feature Methylcobalamin Cyanocobalamin
- Form Active Inactive (requires conversion)
- Neuroprotective Yes Less so
- Detoxifying agent Methyl donor Has cyanide molecule
- Preferred in nerve-related problems
- Side Effects and Precautions
- Often well-tolerated

✓ Very rare side effects: rash, headache, dizziness, nausea
✓ Use with caution in:
✓ Leber's disease (hereditary optic neuropathy)
✓ Renal impairment

➢ *Market & Usage*

- Widely available as OTC supplements and prescription medications
- Common in countries like India, Japan, and the USA
- Typically marketed for:
- Energy supplementation
- Nerve health
- Brain and cognitive function

➢ *Drug Profile: Methylcobalamin*
- **Generic Name:** Methylcobalamin

➢ *Brand Names (Examples):*

- Neurobion Plus
- MeCobalamin Injection
- Methycobal
- Nurokind

➢ *Classification:*

- **Therapeutic Class:** Vitamin B12 Supplement / Hematinic
- **Pharmacologic Class:** Water-soluble vitamin (coenzyme form of Vitamin B12)
- **ATC Code:** B03BA05

➢ *Mechanism of Action:*

Methylcobalamin acts as a coenzyme in the conversion of homocysteine to methionine via the enzyme methionine synthase. This reaction is essential for:

- DNA synthesis
- Myelin sheath formation
- Neuronal repair and maintenance

It also contributes to the synthesis of **S-adenosylmethionine (SAMe)**, a key methyl donor in numerous biochemical processes.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1309

Table 1 Pharmacokinetics:

Absorption	Absorbed in the ileum (enhanced sublingually)
Bioavailability	Variable (oral); high (parenteral)
Distribution	Binds to transcobalamin II; stored in liver
Metabolism	Not extensively metabolized
Excretion	Mainly through urine
Half-life	~6 hours (variable)

➢ *Indications*

- Vitamin B12 deficiency
- Diabetic peripheral neuropathy
- Megaloblastic anemia
- Chronic fatigue and weakness
- Neurological disorders (e.g. Alzheimer's, MS)
- Supportive therapy in ALS (investigational)

Table 2 Dosage Forms & Strengths:

Form	Strengths
Oral Tablets	500 mcg, 750 mcg, 1500 mcg
Sublingual Tablets	500 mcg, 1500 mcg
Injections (IM/IV)	500 mcg/ml, 1000 mcg/ml
Combinations	With B1 (Thiamine), B6 (Pyridoxine)

Table 3 Dosage & Administration (Adults):

Condition	Dosage
B12 deficiency (mild-moderate)	500 mcg – 1500 mcg orally daily

➢ *Contraindications*

- Known hypersensitivity to cobalamins
- **Leber's disease** (hereditary optic neuropathy) – risk of optic nerve atrophy

➢ *Warnings and Precautions*

- Monitor B12 levels in long-term therapy
- May mask symptoms of folate deficiency
- Use with caution in renal dysfunction (high doses)

➢ *Adverse Effects (Rare)*

- Nausea, vomiting
- Headache, dizziness
- Skin rash or itching
- Injection site pain
- Hypersensitivity reactions (very rare)

➢ *Drug Interactions*

- **Chloramphenicol** – may reduce hematologic response
- **Proton pump inhibitors (PPIs)** and **Metformin** – may reduce B12 absorption
- Alcohol – chronic use may impair absorption

➢ *Monitoring Parameters*

- Serum Vitamin B12 levels
- CBC (complete blood count)
- Homocysteine and methylmalonic acid (in suspected deficiency)

➢ *Storage Conditions*

- Store at **20°C to 25°C (68°F to 77°F)**
- Protect from **light** and **moisture**
- Keep injectable vials in the refrigerator if advised
-

➢ *Regulatory Status*

- OTC (Oral/Supplemental) in many countries
- Rx (Injectable) in most regulatory jurisdictions
- Approved by FDA, CDSCO (India), PMDA (Japan), etc.
- Certainly! Here's a concise and professional conclusion for Methylcobalamin, suitable for inclusion in reports, presentations, or product documentation:

IV. CONCLUSION

➢ Methylcobalamin is a vital, biologically active form of **Vitamin B12** with significant therapeutic potential, particularly in the management of **neurological disorders** and **Vitamin B12 deficiency-related conditions**. Its superior bioavailability and direct involvement in critical physiological processes—such as **nerve regeneration**, **DNA synthesis**, and **homocysteine metabolism**—make it a preferred choice over other forms like cyanocobalamin.

➢ With excellent safety, tolerability, and wide clinical applications, Methylcobalamin continues to be a valuable

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1309

agent in both **nutritional supplementation** and **pharmaceutical therapy**, especially in **neuropathy**, **anemia**, and **cognitive support**. Its growing demand in global markets underscores its importance in preventive and therapeutic healthcare

➢

REFERENCE

[1]. Mandel, H., & Shalata, A. (2005).***Methylcobalamin and its role in cellular functions and health*. *Journal of Nutrition, 135*(6), 1329-1334.**

[2]. Vannucchi, M. G., et al. (2002).***Methylcobalamin supplementation in patients with vitamin B12 deficiency-related neuropathy*. *European Journal of Neurology, 9*(4), 383-386.**

[3]. Schaefer, E. J., & Lichtenstein, A. H. (2007).***Vitamin B12 (Cobalamin) Deficiency and Methylcobalamin: Biochemistry and Clinical Implications*. Journal of Clinical Pharmacology, 47(4), 470-476.**

[4]. Watanabe, F., et al. (2007).***Bioavailability of methylcobalamin in humans: a review*. Journal of Nutritional Biochemistry, 18(12), 763-767.**

[5]. Vannucchi, M. G., et al. (2002).***Methylcobalamin supplementation in patients with vitamin B12 deficiency-related neuropathy*. European Journal of Neurology, 9(4), 383-386.**

[6]. Ribaya-Mercado, J. D., & McNeill, G. (2006).***Methylcobalamin as an active form of vitamin B12*. Journal of Nutrition, 136(10), 2690-2694.**

[7]. Sinn, N., & Bryan, J. (2007).***Methylcobalamin and its effects on neurological health*. Journal of Clinical Neurology, 3(2), 65-70.**

[8]. Hansen, R. S. (2007).***Pharmaceutical marketing: A global perspective*. *International Journal of Pharmaceutical and Healthcare Marketing, 1*(3), 203-217.**

[9]. Stern, S., & Stokes, R. (2008).***Pharmaceutical marketing: Ethics and regulation*. *Pharmaceutical Marketing & Management, 4*(2), 45-50.**

[10]. Figueiredo, C., & Nakano, D. (2010).***The role of digital marketing in the pharmaceutical industry: A case study on social media use*. *Journal of Business Research, 63*(4), 387-395.**

[11]. Harris, J. L., & Schwartz, M. B. (2019).***The role of marketing in shaping pharmaceutical product use: The case of off-label marketing*. *American Journal of Public Health, 109*(1), 25-30.**